We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Astrazeneca Plc | LSE:AZN | London | Ordinary Share | GB0009895292 | ORD SHS $0.25 |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
-12.00 | -0.10% | 12,014.00 | 12,012.00 | 12,016.00 | 12,144.00 | 11,960.00 | 12,070.00 | 305,778 | 10:30:28 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Pharmaceutical Preparations | 45.81B | 5.96B | 3.8415 | 31.22 | 185.93B |
Date | Subject | Author | Discuss |
---|---|---|---|
01/3/2022 08:09 | Proof is here from the uk govt yellow card reporting system, where in small print it says only 1-10% of reported events and this is just for the az shots and there are many more blood and heart related illnesses | jimarilo | |
28/2/2022 14:50 | Stifel Starts AstraZeneca Coverage With Buy Rating 02/28/2022 | 11:05am GMT (MT Newswires) -- Stifel on Monday initiated coverage of AstraZeneca (AZN.L) with a buy rating and set the price target at 123 pounds sterling ($164.61). | beckers2008 | |
25/2/2022 10:24 | 02/24/2022 | 05:57pm GMT SVB Leerink Adjusts AstraZeneca's Price Target to $70 from $65, Maintains Outperform Rating | beckers2008 | |
24/2/2022 11:20 | Growth - today is ex div date with a dividend of 145.3p so deduct that amount down today from the overall share price of AZN | hjs | |
24/2/2022 09:57 | The world is mad! | gateside | |
24/2/2022 09:30 | Down 3%, the world must be mad | growthpotential | |
24/2/2022 00:48 | Now that’s a catchy tune ..... Dare anyone to sing this up the high street LOL Carl Vernon 134K subscribers | jimarilo | |
23/2/2022 17:37 | Ex-div tomorrow for 145.3p | gateside | |
21/2/2022 21:10 | Yes the positive RNS announcements are so frequent. An excellent run company. | gateside | |
21/2/2022 16:25 | 2.5 billion jabs ... hundreds of millions saved. Never mind the huge leaps forward across their range of products. A fantastic company .. every second day there's an announcement. Could double from here imo. Well done the scientists ... | mapocho | |
21/2/2022 16:11 | Very satisfactory. | patientcapital | |
21/2/2022 11:10 | This morning's statement is a big deal | wish i wasnt in rbs | |
20/2/2022 02:19 | mapocho, millions of dead around the world due to the jab, will disagree with you The usa reporting system vaers.......reports 25,000 dead from the jab In small print vaers says only 1-10% of deaths reported FOI reply public health scotland ..8th Dec - 28th May 2021 5522 died in scotland within 28 days of a jab | jimarilo | |
20/2/2022 02:12 | Military Arrests SCJ Sonia Sotomayor By Michael Baxter -February 18 U.S. Marines on Wednesday arrested Supreme Court Justice Sonia Sotomayor following a 3-month investigation into whether she had accepted cash payoffs for rulings favoring mask and vaccination mandates and knowingly made false statements to amplify Covid fear. The truth is coming ..... | jimarilo | |
16/2/2022 19:58 | Back in for more today. | woodyjmw | |
15/2/2022 16:16 | Fantastic company here. Saving millions of lives also. | mapocho | |
15/2/2022 13:57 | Keep going RR. | woodyjmw | |
15/2/2022 11:53 | Well done the scientists. | philanderer | |
15/2/2022 11:53 | As well as another good news story; ASTRAZENECA : JP Morgan remains its Buy rating 02/15/2022 | 11:05am GMT JP Morgan is positive on the stock with a Buy rating. The target price continues to be set at GBX 10000. | beckers2008 | |
14/2/2022 15:08 | Just take a look at the manipulated vaers numbers and the yellow card reporting system They are both corrupt, but still show thousands of deaths The real numbers are in the millions .......including kids and pregnant women | jimarilo |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions